Transcatheter annuloplasty system for tricuspid and mitral regurgitation
Mitralign Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. It has developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the US alone. Its unique system provides a new solution for interventional cardiologists and their patients.
Are you the next big thing?
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!